Over the past two years, the therapeutic landscape of vitiligo has changed more than in the previous twenty years. The approval of the first specific drug, the launch of systemic phase 3 studies, and the evolution of integrated protocols have created new possibilities, but also new confusion. This page gathers in an organized way all the options currently available in Italy: how they work, what the studies show, how much they cost, and what their limitations are.<\/p>\n
In the 26 years during which I have treated patients affected by vitiligo, the most frequent question has never changed: \u201cDoctor, what should I do?\u201d<\/em>. Over the last two years, the answer has become more complex, not simpler, and patients risk getting lost among partial information and promises that are not always verifiable.<\/p>\n This page honestly presents everything that today a dermatologist can propose to a patient with vitiligo in Italy. I have also included approaches that we do not directly practice at our Institute: the credibility of anyone proposing a protocol is also measured by the ability to discuss alternatives. Where evidence exists, I cite the studies. Where data are lacking, I state it clearly.<\/p>\n Vitiligo therapies can be divided into two major families. Recognizing which family a treatment belongs to is the first step in evaluating its appropriateness.<\/p>\n Local approaches<\/strong> act exclusively on the skin, without modifying the systemic immune mechanisms that drive the disease. These include corticosteroids and calcineurin inhibitors in cream form, topical ruxolitinib, and melanocyte grafting. Their effectiveness is greatest on the treated areas, but they do not act on the tendency toward progression or on untreated areas.<\/p>\n Systemic and integrated approaches<\/strong> act on the immune origin of the disease and on the skin, considering vitiligo as the cutaneous manifestation of an autoimmune disorder that also involves the intestine, microbiota, and vitamin D. This category includes the ImmunoNova Protocol<\/a>, systemic JAK inhibitors currently in phase 3 studies, and UVB phototherapy as part of integrated programs. The goal is not only repigmentation, but also disease stabilization and reduction of the risk of relapse.<\/p>\n Choosing between a local and a systemic approach is not a matter of preference: it depends on the extent of vitiligo, its activity, and the presence of other signs of immune dysregulation.<\/p>\n<\/blockquote>\n Ruxolitinib is a Janus kinase inhibitor (JAK1 and JAK2) in a 1.5% cream formulation, approved by the EMA in 2023 and reimbursed in Italy by the National Health Service through a therapeutic plan. It is indicated for non-segmental facial vitiligo in adults and adolescents from 12 years of age, with body involvement between 3% and 10%. It locally blocks the JAK-STAT pathway that contributes to melanocyte destruction.<\/p>\n The phase 3 TRuE-V1 and TRuE-V2 studies, involving 674 patients, showed significant facial repigmentation (F-VASI75) in 28.2% of patients after 6 months<\/strong> and in approximately 50% after 12 months<\/strong> of twice-daily application. Results on the body are more modest: only 11.2% achieved significant repigmentation (T-VASI75) at 6 months, a threshold later reduced to T-VASI50.<\/p>\n Approximately 50% of patients reported at least one side effect (acne, itching, nasopharyngitis, headache). The drug has an estimated price of \u20ac1,200 for 100 g of cream. Results tend to diminish after discontinuation. The drug is indicated mainly<\/em> for facial patches: for patients with extensive body vitiligo, the benefits are limited. I have dedicated a more in-depth article to ruxolitinib<\/a>, including a detailed comparison with topical tacrolimus.<\/p>\n Oral JAK inhibitors represent the research frontier for extensive forms of vitiligo involving more than 10% of body surface area. Povorcitinib<\/strong> is currently in phase 3 studies, involving several university centers in Italy, including the Gemelli University Hospital. The objective is to provide a systemic response for patients with generalized vitiligo.<\/p>\n Preliminary data are encouraging but still incomplete. The safety profile requires caution: systemic JAK inhibitors are associated with cardiovascular, infectious, and hematological risks. A 2024 study published in Blood<\/em> analyzed patients with myelofibrosis treated with oral ruxolitinib over prolonged periods, reporting 12 deaths from metastatic non-melanoma skin cancers \u2014 a finding that cannot be directly transferred to vitiligo treatment doses, but which requires careful monitoring.<\/p>\n Regulatory approval for vitiligo in Europe is not expected before 2027\u20132028. Today, these drugs are accessible only through enrollment in clinical trials.<\/p>\n Narrowband UVB phototherapy (311 nm) is the most studied and established treatment for vitiligo, recommended for over thirty years by international dermatological guidelines. It stimulates repigmentation by acting on residual melanocytes in hair follicles and locally modulates immune activity. Its safety profile, unlike uncontrolled sun exposure or tanning beds, is widely documented.<\/p>\n It can be performed in two ways. The first is outpatient treatment<\/strong>, with 2\u20133 weekly sessions at a clinic, which is logistically demanding and often leads to early discontinuation. The second is home-based treatment<\/strong>, using a certified lamp prescribed by a physician: it eliminates travel, allows brief daily sessions, and dramatically improves adherence. In the ImmunoNova Protocol we exclusively use the home-based modality: phototherapy performed for a few minutes every day produces better results than longer sessions with frequent absences.<\/p>\n As an isolated therapy, phototherapy is effective but limited: our data show that topical therapies alone achieve approximately 45% improvement, compared to the 84% observed in patients with complete adherence to the integrated protocol.<\/p>\n Autologous melanocyte stem cell grafting is an outpatient surgical procedure. It involves harvesting a small sample of the patient\u2019s pigmented skin, isolating melanocytes in the laboratory, and transplanting them onto depigmented areas prepared with controlled dermabrasion. In Italy, the best-known technique is Rigenera\u00ae<\/strong>.<\/p>\n Effectiveness on treated areas is very high, generally between 70% and 90% repigmentation. However, the technique has two precise limitations. It requires stable vitiligo for at least 12 months<\/strong>: if the disease is active, new patches may appear elsewhere. It does not resolve the autoimmune cause: it is a strategy for definitive repigmentation of grafted areas, not a treatment for vitiligo itself.<\/p>\n For this reason, in the Institute\u2019s experience, grafting is typically the final stage<\/em> of a therapeutic pathway: first the disease is stabilized with an integrated protocol, then, when patches no longer respond to medical therapies, grafting is considered for difficult areas such as hands, feet, and peripheral zones.<\/p>\n Topical corticosteroids (clobetasol, mometasone) and calcineurin inhibitors (tacrolimus, pimecrolimus) are the historical topical therapies for vitiligo. They act by locally reducing the inflammatory response that destroys melanocytes. They can be prescribed by dermatologists, are partially reimbursed, and still represent first-line therapy for mild forms in many Italian hospital protocols.<\/p>\n As monotherapy, they have an estimated effectiveness of around 45%, but often with temporary results. Prolonged corticosteroid use on the face and delicate areas carries a risk of skin atrophy and telangiectasia; calcineurin inhibitors are safer in the long term. A multicenter study on tacrolimus 0.1% showed an F-VASI75 of 50% at 3 months \u2014 a result comparable to ruxolitinib over longer periods, at a significantly lower cost. In the ImmunoNova Protocol, these molecules are an integral part of targeted topical therapy, used during active phases in combination with the other pillars.<\/p>\n The ImmunoNova Protocol is the approach developed at the Dermacademy Institute over 26 years of clinical research. It starts from a simple assumption: vitiligo is a systemic autoimmune disease<\/strong>, not an isolated skin problem. The skin is the visible target, not the origin of the process.<\/p>\n The protocol is based on five pillars: objective clinical evaluation with the Vitiligo Activity Index and Wood\u2019s lamp, correction of gastrointestinal dysfunctions, rebalancing of the microbiota and vitamin D, home-based narrowband UVB phototherapy, and targeted topical therapies calibrated according to the phase of the disease. These are not applied sequentially but in an integrated way, adapting to active and stable phases.<\/p>\n The clinical case series includes 4,136 patients followed over the last 8 years, with 26,532 visits documented through photography, VAI calculation, and adherence tracking. In patients with complete adherence, clinical improvement was observed in 84% of cases<\/strong>. The cost for the patient is \u20ac280 for the initial consultation and \u20ac220 for follow-up visits approximately every 3 months<\/strong>; to this must be added the therapeutic supports themselves (parapharmaceuticals, creams, lamp), which the patient will purchase independently. ImmunoNova is not necessarily an alternative to the other treatments described: it can integrate home-based phototherapy, topical therapies, and, in final stages, melanocyte grafting. Its distinctive feature is the overall logic: not to chase the repigmentation of a single patch, but to restore stable immune balance over time. Learn more about how the protocol works<\/a>.<\/p>\n An overview of the main therapeutic options available for vitiligo in 2026, across four key dimensions.<\/p>\n There is no universal answer. Every pathway must be discussed individually with a physician experienced in vitiligo. However, some general guidance can be provided.<\/p>\n The child or adolescent with early vitiligo<\/strong> typically benefits from an integrated protocol aimed at stopping progression before the disease spreads. In younger patients, response to therapy is often better than in adults, especially when treatment is started early.<\/p>\n The adult with patches only on the face<\/strong> may consider two options: topical ruxolitinib through the National Health Service, or a more structured integrated protocol. The choice depends on the presence of signs of disease activity elsewhere and the patient\u2019s clinical history. The patient with generalized vitiligo<\/strong>, involving large body areas, is instead the typical candidate for a systemic approach: ImmunoNova or clinical trials with systemic JAK inhibitors.<\/p>\n Two particular cases. The patient with stabilized vitiligo<\/strong> and residual patches on the hands may consider melanocyte grafting as the final stage of an integrated pathway. The patient with associated autoimmune diseases<\/strong> (Hashimoto\u2019s thyroiditis, type 1 diabetes, celiac disease) may particularly benefit from a systemic approach, because the presence of multiple diseases suggests broader immune dysregulation.<\/p>\n Regardless of the treatment, some clinical principles should guide the patient\u2019s choice.<\/p>\n The therapeutic landscape of vitiligo in 2026 offers more options than ever before. Ruxolitinib has opened an important path, but with precise indications and documented limitations. Systemic JAK inhibitors represent the future for extensive forms, but that future is not here yet. Classical topical therapies still retain a role, especially within integrated protocols. Melanocyte grafting remains an advanced stage for selected areas. ImmunoNova addresses the disease for what it is: a systemic autoimmune condition requiring a systemic approach.<\/p>\n Choosing the right pathway does not depend on the newest treatment, but on the match between the characteristics of the individual patient\u2019s disease and the most appropriate clinical strategy. The initial specialist consultation, with an objective evaluation of disease activity, remains the necessary starting point for any informed therapeutic choice.<\/p>\nTwo families of approaches, two different logics<\/h2>\n
\n
Topical ruxolitinib (Opzelura\u00ae<\/sup>)<\/h2>\n
Systemic JAK inhibitors (oral tablets)<\/h2>\n
Narrowband UVB phototherapy<\/h2>\n
Autologous melanocyte grafting<\/h2>\n
Classical topical therapies<\/h2>\n
ImmunoNova Protocol<\/h2>\n
Comparative summary<\/h2>\n
\n\n
\n \nTherapy<\/th>\n Documented effectiveness<\/th>\n Treated areas<\/th>\n Annual cost<\/th>\n<\/tr>\n<\/thead>\n \n ImmunoNova Protocol<\/th>\n 84%<\/strong> (complete adherence)<\/td>\n Whole body<\/td>\n \u20ac280 first consultation \u00b7 \u20ac220 follow-ups<\/td>\n<\/tr>\n \n Topical ruxolitinib<\/th>\n 28\u201350% (face only)<\/td>\n Face only<\/td>\n \u20ac14,400\u201328,800 (NHS)<\/td>\n<\/tr>\n \n Systemic JAK inhibitors<\/th>\n Phase 3 studies<\/td>\n Systemic<\/td>\n Only in clinical trials<\/td>\n<\/tr>\n \n Narrowband UVB (alone)<\/th>\n 45\u201360%<\/td>\n Whole body<\/td>\n Variable (mixed)<\/td>\n<\/tr>\n \n Melanocyte grafting<\/th>\n 70\u201390% (treated areas)<\/td>\n Stable patches<\/td>\n One-time (patient)<\/td>\n<\/tr>\n \n Classical topical therapies (alone)<\/th>\n ~45%<\/td>\n Limited areas<\/td>\n Low (mixed)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Which therapy for which patient<\/h2>\n
Three criteria for choosing well<\/h2>\n
\n
In summary<\/h2>\n